Summary
Pancreatic cancer (International Statistical Classification of Diseases and Related Health Problems, 10th Revision [ICD-10] code = C25) is the seventh leading cause of cancer deaths worldwide. Pancreatic cancer occurs when cells in the pancreas develop mutations in their DNA and grow uncontrollably. These accumulating cells form a tumor. Untreated pancreatic cancer spreads to nearby organs and blood vessels. PDAC or pancreatic exocrine cancer is the most common type of pancreatic cancer and begins in the cells that line the ducts of the pancreas. PDAC is an aggressive form of pancreatic cancer where approximately 60-80% of patients already have distant metastasis at presentation.
The publisher's epidemiologists used age- and sex-specific diagnosed incidence and prevalence rates to forecast the diagnosed incident and prevalent cases, considering the significant relationship between age and incidence. The publisher's epidemiologists applied country-specific incidence rates of pancreatic cancer, wherever available, to each country’s population to obtain the number of estimated diagnosed incident cases.
The following data describes epidemiology of PDAC cases. In 2019, the 8MM had 178,128 diagnosed incident cases of PDAC. This is expected to increase to 224,769 diagnosed incident cases by 2029, at an Annual Growth Rate (AGR) of 2.62%. This increase is partly attributed to the moderately rising trend in incidence in the 8MM, combined with underlying demographic changes in the respective markets. In the 8MM, the five-year diagnosed prevalent cases of PDAC will increase from 113,292 cases in 2019 to 140,914 cases in 2029, at an AGR of 2.44%. The early diagnosis and development of more effective therapies, particularly for elderly patients, would improve survival from PDAC.
Scope
Reasons to Buy
The PDAC Epidemiology series will allow you to -
Pancreatic cancer (International Statistical Classification of Diseases and Related Health Problems, 10th Revision [ICD-10] code = C25) is the seventh leading cause of cancer deaths worldwide. Pancreatic cancer occurs when cells in the pancreas develop mutations in their DNA and grow uncontrollably. These accumulating cells form a tumor. Untreated pancreatic cancer spreads to nearby organs and blood vessels. PDAC or pancreatic exocrine cancer is the most common type of pancreatic cancer and begins in the cells that line the ducts of the pancreas. PDAC is an aggressive form of pancreatic cancer where approximately 60-80% of patients already have distant metastasis at presentation.
The publisher's epidemiologists used age- and sex-specific diagnosed incidence and prevalence rates to forecast the diagnosed incident and prevalent cases, considering the significant relationship between age and incidence. The publisher's epidemiologists applied country-specific incidence rates of pancreatic cancer, wherever available, to each country’s population to obtain the number of estimated diagnosed incident cases.
The following data describes epidemiology of PDAC cases. In 2019, the 8MM had 178,128 diagnosed incident cases of PDAC. This is expected to increase to 224,769 diagnosed incident cases by 2029, at an Annual Growth Rate (AGR) of 2.62%. This increase is partly attributed to the moderately rising trend in incidence in the 8MM, combined with underlying demographic changes in the respective markets. In the 8MM, the five-year diagnosed prevalent cases of PDAC will increase from 113,292 cases in 2019 to 140,914 cases in 2029, at an AGR of 2.44%. The early diagnosis and development of more effective therapies, particularly for elderly patients, would improve survival from PDAC.
Scope
- Pancreatic Cancer Epidemiology Report provides an overview of the risk factors and global trends of pancreatic ductal adenocarcinoma (PDAC) in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and Urban China).
- This report also includes a 10-year epidemiological forecast for the following segmentations across the 8MM: diagnosed incident cases of pancreatic cancer and PDAC; PDAC segmented by sex and age (18-29 years, 30-39 years, 40-49 years, 50-59 years, 60-69 years, 70-79 years, and 80 years and older); diagnosed five-year prevalent cases PDAC; diagnosed incident cases of PDAC by cancer staging; and diagnosed incident cases of PDAC by biomarkers.
- The Pancreatic Cancer Epidemiology Report is written and developed by Masters- and PhD-level epidemiologists.
- The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.
Reasons to Buy
The PDAC Epidemiology series will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global pancreatic cancer and PDAC market.
- Quantify patient populations in the global PDAC market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the PDAC cancer stages that present the best opportunities for PDAC therapeutics in each of the markets covered.
- Understand magnitude of PDAC market by biomarkers.
Table of Contents
1 Table of Contents
2 Pancreatic Cancer: Executive Summary
3 Epidemiology
4 Appendix
List of Tables
List of Figures
